Home Account PricesPerformance Funds Retirement College Education

New window: AdvantageVoice - Opening the door to investment conversations. Read our new blog.
Fundamental Growth Equity | December 2011

In a challenging economy, innovative growth companies have a distinct edge

By Thomas Pence, CFA, and Michael Smith, CFA—Portfolio Managers Enterprise Fund

Share This PageShare this
Links to external websites are not sponsored by Wells Fargo. Wells Fargo has provided these links for your convenience, but does not endorse and is not responsible for the content, links, privacy policy, or security policy of these websites.

As recently as two months ago, some economists and investors feared that the global economy was on the brink of collapse. With the year winding down, it now appears that those fears may have been exaggerated. However, while the economy may avoid another recession, growth is unlikely to accelerate dramatically in the coming months.

As we enter the later stages of the current economic cycle, companies that can consistently generate robust sales growth may become increasingly scarce—and therefore, more valuable. We believe that some of the most successful growth companies will be those that can drive organic sales growth through innovation. By selectively favoring such companies, investors may be well positioned to navigate the period ahead.

Opportunities in several sectors

Innovative companies typically provide unique products or services that benefit from resilient demand, potentially allowing them to grow against a variety of economic backdrops. In fact, even when the economy is not humming along briskly, these companies may succeed in grabbing additional market share from competitors. Surveying the current market landscape, we believe that innovative growth stories can be found across market capitalizations and in several different sectors.

In health care, for example, Alexion Pharmaceuticals* has developed innovative products that set the company apart from other biotechnology firms. Alexion has delivered strong sales growth, fueled by geographic expansion and the success of its flagship drug Soliris—trends that look poised to continue. Soliris is used to treat rare diseases such as atypical hemolytic-uremic syndrome and paroxysmal nocturnal hemoglobinuria. We expect additional indications for the drug to ultimately be approved, enhancing its sustainable demand profile due to the limited options now available for treating these rare diseases.

Innovation has also been a critical component of success for some consumer discretionary companies. For instance, lululemon athletica's* solid sales growth in recent years can be traced largely to its technological innovations in the athletic apparel market for women. The company has produced clothing with unique fabrics that combine functionality and fashion, particularly for yoga exercises. We believe that its future growth prospects are significant because of the potential for further U.S. expansion, innovative apparel solutions for activities beyond yoga, and a promising new athletic-apparel concept aimed at the youth market.

Industrials firms—such as Rockwell Automation*—that can help customers "do more with less," thereby boosting their productivity levels and reducing their costs, should also fare quite well in a challenging economic environment. Rockwell Automation provides a range of power, control, and information solutions and services that are designed to solve its customers' manufacturing problems. Armed with these innovative offerings, the company has generated impressive sales growth, supported by both "catch-up" spending in developed economies and ongoing demand from emerging markets countries.

Innovative companies have posted strong sales growth, outpacing their sector averages

Year-over-year (YOY) sales growth
(based on most recent quarter reported as of 11-17-11)

Source: FactSet. The Russell 3000 Growth Index measures the performance of the broad growth segment of the U.S. equity universe. It includes those Russell 3000® Index companies with higher price-to-book ratios and higher forecasted growth values. The health care, consumer discretionary, and industrials components of the index comprise companies that reside within those respective sectors. You cannot invest directly in an index.
Past performance is no guarantee of future results.


Concluding observations

Given that economic growth is likely to remain sluggish for the foreseeable future, it may become more difficult to find fundamentally sound companies with prospects for strong and sustainable growth. As a result, those that can consistently achieve rapid, organic sales growth should command a valuation premium going forward. In our view, the best opportunities for outperformance lie in innovative companies with powerful secular tailwinds that have enabled them to carve out profitable niches within their respective sectors. As always, we think that a bottom-up, "surround the company" research approach is well suited to identifying such opportunities across the marketcapitalization spectrum.



Thomas Pence, CFA, and Michael Smith, CFA, are also portfolio managers for the: Discovery Fund and Omega Growth Fund

Thomas Pence, CFA, Michael Harris, CFA, and Michael Smith, CFA, are portfolio managers for the: Endeavor Select Fund

Thomas Pence, CFA, and Michael Harris, CFA, are portfolio managers for the: Capital Growth Fund




*The stocks mentioned represented the following percentages of the above-referenced funds as of 9-30-11: Alexion Pharmaceuticals, Inc. = 0.84% of the Wells Fargo Advantage Capital Growth Fund, 1.49% of the Wells Fargo Advantage Endeavor Select Fund, 2.55% of the Wells Fargo Advantage Enterprise Fund, 2.15% of the Wells Fargo Advantage Omega Growth Fund, and 1.98% of the Wells Fargo Advantage Discovery Fund; lululemon athletica inc.= 1.20% of the Wells Fargo Advantage Capital Growth Fund, 0.97% of the Wells Fargo Advantage Enterprise Fund, and 0.95% of the Wells Fargo Advantage Omega Growth Fund; Rockwell Automation, Inc. = 1.41% of the Wells Fargo Advantage Enterprise Fund. Holdings are subject to change and may have changed since the date specified.

The views expressed and any forward-looking statements are as of 11-30-11 and are those of the fund managers and/or Wells Fargo Funds Management, LLC. Discussions of individual securities, or the markets generally, or any Wells Fargo Advantage Fund are not intended as individual recommendations. Future events or results may vary significantly from those expressed in any forward-looking statements; the views expressed are subject to change at any time in response to changing circumstances in the market. Wells Fargo Funds Management, LLC, disclaims any obligation to publicly update or revise any views expressed or forward-looking statements.

Stock fund values fluctuate in response to the activities of individual companies and general market and economic conditions. Foreign investments are especially volatile and can rise or fall dramatically due to differences in the political and economic conditions of the host country. These risks are generally intensified in emerging markets. The use of derivatives may reduce returns and/or increase volatility. Certain investment strategies tend to increase the total risk of an investment (relative to the broader market). Some of these funds are exposed to regional risk and smaller-company securities risk. Consult a fund's prospectus for additional information on these and other risks.


Back to Recent Investment Perspectives

  • Not FDIC Insured
  • No Bank Guarantee
  • May Lose Value

Wells Fargo Advantage Funds

  • Individual Investors · 1-800-359-3379
  • Investment Professionals · 1-888-877-9275
  • Institutional Sales Professionals · 1-866-765-0778